Vericel Corp
For the period ended Jun 30, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended June 30, 2025, the following Section 16 officers or directors adopted, modified orterminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).
On May 12, 2025, Kevin McLaughlin, amember of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 35,000 shares of our common stock between November 10, 2025 and November 30, 2026;
On May 23, 2025, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 7,500 shares of our common stock between September 2, 2025 and August 28, 2026; and
On May 30, 2025, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 37,847 shares of our common stock between September 2, 2025 and August 28, 2026.
There were no “non-Rule 10b5-1 trading arrangements” (as defined in Item 408 of Regulation S-K of the Exchange Act)adopted, modified orterminated during the three months ended June 30, 2025 by our Section 16 officers or directors.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.